Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.
Identifieur interne : 002059 ( Main/Merge ); précédent : 002058; suivant : 002060Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.
Auteurs : L Miller ; Joseph Jankovic [États-Unis]Source :
- Archives of internal medicine [ 0003-9926 ] ; 1989.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Metoclopramide.
- chemically induced : Basal Ganglia Diseases, Parkinson Disease, Secondary.
- etiology : Dyskinesia, Drug-Induced.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged.
Abstract
Metoclopramide, a dopamine-2 receptor antagonist used for various gastrointestinal disorders, may cause or exacerbate a variety of extrapyramidal movement disorders. To draw attention to the frequent occurrence of metoclopramide-induced movement disorders, we identified and studied 16 patients who had been exposed to this neuroleptic. The average age at onset was 63 years (range, 24 to 85 years), and women outnumbered men 3 to 1. Tardive dyskinesia was the most common movement disorder (n = 10 [63%]). Five patients had metoclopramide-induced parkinsonism, 1 patient had tardive dystonia, and 1 patient had akathisia. The average duration of exposure prior to onset of movement disorders was 12 months (range, 1 day to 4 years). Therapy was continued for an average of 6 months (range, 1 day to 2 years) after the onset of symptoms, reflecting clinical nonrecognition of the movement disorder and its relationship to metoclopramide. To prevent persistent and disabling movement disorders, long-term use of metoclopramide should be avoided, and patients should be carefully observed for potential neurologic reactions.
PubMed: 2684075
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000315
- to stream PubMed, to step Curation: 000315
- to stream PubMed, to step Checkpoint: 000310
- to stream Ncbi, to step Merge: 000537
- to stream Ncbi, to step Curation: 000537
- to stream Ncbi, to step Checkpoint: 000537
Links to Exploration step
pubmed:2684075Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.</title><author><name sortKey="Miller, L G" sort="Miller, L G" uniqKey="Miller L" first="L" last="Miller">L Miller</name><affiliation><nlm:affiliation>Department of Family Medicine, Baylor College of Medicine, Houston, Tex. 77030.</nlm:affiliation><wicri:noCountry code="subField">Tex</wicri:noCountry></affiliation></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1989">1989</date><idno type="RBID">pubmed:2684075</idno><idno type="pmid">2684075</idno><idno type="wicri:Area/PubMed/Corpus">000315</idno><idno type="wicri:Area/PubMed/Curation">000315</idno><idno type="wicri:Area/PubMed/Checkpoint">000310</idno><idno type="wicri:Area/Ncbi/Merge">000537</idno><idno type="wicri:Area/Ncbi/Curation">000537</idno><idno type="wicri:Area/Ncbi/Checkpoint">000537</idno><idno type="wicri:doubleKey">0003-9926:1989:Miller L:metoclopramide:induced:movement</idno><idno type="wicri:Area/Main/Merge">002059</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.</title><author><name sortKey="Miller, L G" sort="Miller, L G" uniqKey="Miller L" first="L" last="Miller">L Miller</name><affiliation><nlm:affiliation>Department of Family Medicine, Baylor College of Medicine, Houston, Tex. 77030.</nlm:affiliation><wicri:noCountry code="subField">Tex</wicri:noCountry></affiliation></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j">Archives of internal medicine</title><idno type="ISSN">0003-9926</idno><imprint><date when="1989" type="published">1989</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Basal Ganglia Diseases (chemically induced)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Metoclopramide (adverse effects)</term><term>Middle Aged</term><term>Parkinson Disease, Secondary (chemically induced)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Metoclopramide</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Metoclopramide, a dopamine-2 receptor antagonist used for various gastrointestinal disorders, may cause or exacerbate a variety of extrapyramidal movement disorders. To draw attention to the frequent occurrence of metoclopramide-induced movement disorders, we identified and studied 16 patients who had been exposed to this neuroleptic. The average age at onset was 63 years (range, 24 to 85 years), and women outnumbered men 3 to 1. Tardive dyskinesia was the most common movement disorder (n = 10 [63%]). Five patients had metoclopramide-induced parkinsonism, 1 patient had tardive dystonia, and 1 patient had akathisia. The average duration of exposure prior to onset of movement disorders was 12 months (range, 1 day to 4 years). Therapy was continued for an average of 6 months (range, 1 day to 2 years) after the onset of symptoms, reflecting clinical nonrecognition of the movement disorder and its relationship to metoclopramide. To prevent persistent and disabling movement disorders, long-term use of metoclopramide should be avoided, and patients should be carefully observed for potential neurologic reactions.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002059 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002059 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:2684075
|texte= Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:2684075" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |